Navigation Links
'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Date:12/27/2007

ENGLEWOOD, Colo., Dec. 27 /PRNewswire/ -- The "Clinical and Economical Considerations For IV Push Drug Delivery" technical paper -- authored by Industry Expert Richard Rosenfeld, RPh, MBA, for Baxa Corporation -- is now accessible at http://expert411.com/_wsn/page16.html for media and professional reference. The paper is an overview of the historical background for IV push and a model for implementation of a successful program.

IV push of cephalosporin antibiotics and other drugs is an alternative method of administration that can be safe, efficacious and cost effective. This paper concentrates on IV push of cefazolin as a case study, since it is a high-use cephalosporin with physical and chemical properties similar to other drugs that can be administered by the IV push method.

Rosenfeld has personally implemented the use of IV push antibiotics within two hospital systems. During the first year that this IV push program was in place, more than 50,000 doses of cefazolin were administered by the IV push method with no occurrences of phlebitis or adverse drug events directly associated with the change in the administration method of this drug. The paper discusses the economical advantages of moving to IV push, as well as the resulting nurse satisfaction and patient benefits seen through the resulting research followup.

Executive Director of Pharmacy Management for the Scripps Health Hospital System in San Diego, CA, Rosenfeld has responsibility for all system pharmacy services through his position with Cardinal Technology and Services. Prior to joining the Scripps Health team, he served as a consultant at Sharp Healthcare, a five-hospital IDN in San Diego, California, where the IV push method of administration for cephalosporins was implemented.

Rosenfeld earned a BS in Pharmacy from Ferris State University and a BA in Chemistry from San Diego State University. He holds an MBA from California State University, San Marcos.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key products include the PadLock(R) Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM) Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at http://www.baxa.com.

Contacts:

Marian Robinson, Vice President, Marketing

Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157

Email: marian.robinson@baxa.com

http://www.baxa.com

Maggie Chamberlin Holben, APR, Absolutely Public Relations

303.984.9801, 303.669.3558

Email: maggie@absolutelypr.com

http://www.absolutelypr.com


'/>"/>
SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... (PRWEB) September 21, 2017 , ... The 3rd ... to review the latest knowledge on these products, which are increasingly used in ... the impact of Biostimulants on Plant Nutrition, Abiotic Stresses, Plant Growth and Development, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... who enable the world’s most progressive pharma and biotech organizations to do more ... top pharma and biotech events in Q4. , DrugDev will demonstrate DrugDev Spark™, ...
(Date:9/21/2017)... S.C. (PRWEB) , ... September 21, 2017 , ... ... turned bright neon green this month, the response was swift and efficient thanks ... ( RRWQG ). RRWQG is made up of more than 50 stakeholders, including ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... today announced the election of Paul Hermes, Entrepreneur in Residence at Medtronic, Inc., ... Biorez has developed a proprietary, tissue-engineered scaffold for anterior cruciate ligament (ACL) reconstruction ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):